<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0001297'>Stroke</z:hpo> is a leading cause of mortality and disability </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="17154">Nicotinamide</z:chebi> phosphoribosyltransferase (Nampt) is the rate-limiting enzyme in mammalian <z:chebi fb="0" ids="13389">nicotinamide adenine dinucleotide</z:chebi> (<z:chebi fb="0" ids="13389">NAD</z:chebi>)(+) biosynthesis and contributes to cell fate decisions </plain></SENT>
<SENT sid="2" pm="."><plain>However, the role of Nampt in brain and <z:hpo ids='HP_0001297'>stroke</z:hpo> remains to be investigated </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We used lentivirus-mediated Nampt overexpression and knockdown to manipulate Nampt expression and explore the effects of Nampt in neuronal survival on ischemic stress both in vivo and in vitro </plain></SENT>
<SENT sid="4" pm="."><plain>We also used <z:chebi fb="3" ids="16335">adenosine</z:chebi> monophosphate (<z:chebi fb="47" ids="16027,28971">AMP</z:chebi>)-activated kinase-α2 (AMPKα2) and silent mating type information regulation 2 homolog 1 (SIRT1) knockout mice to investigate the underlying mechanisms of Nampt neuroprotection </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Nampt inhibition by a highly-specific Nampt inhibitor, FK866, aggravated <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> in experimentally <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> rats, whereas Nampt overexpression in local brain and Nampt enzymatic product <z:chebi fb="0" ids="50383">nicotinamide mononucleotide</z:chebi> (NMN) reduced <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced cerebral injuries </plain></SENT>
<SENT sid="6" pm="."><plain>Nampt overexpression and knockdown regulated neuron survival via the AMPK pathway </plain></SENT>
<SENT sid="7" pm="."><plain>Neuroprotection of Nampt was abolished in AMPKα2(-/-) neurons </plain></SENT>
<SENT sid="8" pm="."><plain>In neurons, Nampt positively modulated <z:chebi fb="0" ids="15846">NAD(+)</z:chebi> levels and thereby controlled SIRT1 activity </plain></SENT>
<SENT sid="9" pm="."><plain>SIRT1 coprecipitated with serine/threonine kinase 11 (LKB1), an upstream kinase of AMPK, and promoted LKB1 deacetylation in neurons </plain></SENT>
<SENT sid="10" pm="."><plain>Nampt-induced LKB1 deacetylation and AMPK activation disappeared in SIRT1(-/-) neurons </plain></SENT>
<SENT sid="11" pm="."><plain>In contrast, Ca(2+) /calmodulin-dependent protein kinase kinase-β (CaMKK-β), another upstream kinase of AMPK, was not involved in the neuroprotection of Nampt </plain></SENT>
<SENT sid="12" pm="."><plain>More important, Nampt overexpression-induced neuroprotection was abolished in SIRT1(+/-) and AMPKα2(-/-) mice </plain></SENT>
<SENT sid="13" pm="."><plain>INTERPRETATION: Our findings reveal that Nampt protects against <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> through rescuing neurons from <z:hpo ids='HP_0011420'>death</z:hpo> via the SIRT1-dependent AMPK pathway and indicate that Nampt is a new therapeutic target for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>